Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1232 | 0.980 |
Why?
|
| Colorectal Neoplasms | 7 | 2024 | 561 | 0.980 |
Why?
|
| Leucovorin | 4 | 2024 | 50 | 0.830 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2024 | 489 | 0.530 |
Why?
|
| Fluorouracil | 4 | 2024 | 128 | 0.430 |
Why?
|
| Organoplatinum Compounds | 3 | 2024 | 29 | 0.380 |
Why?
|
| Microsatellite Instability | 3 | 2024 | 36 | 0.350 |
Why?
|
| Camptothecin | 2 | 2024 | 76 | 0.340 |
Why?
|
| Benzimidazoles | 1 | 2024 | 129 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 6371 | 0.190 |
Why?
|
| Vomiting, Anticipatory | 1 | 2020 | 1 | 0.170 |
Why?
|
| Nursing Care | 1 | 2020 | 10 | 0.170 |
Why?
|
| Mindfulness | 1 | 2020 | 20 | 0.170 |
Why?
|
| Nausea | 1 | 2020 | 97 | 0.170 |
Why?
|
| Deoxycytidine | 2 | 2018 | 76 | 0.160 |
Why?
|
| Hexanones | 1 | 2018 | 4 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 724 | 0.150 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 993 | 0.140 |
Why?
|
| Aged | 9 | 2024 | 19094 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1004 | 0.120 |
Why?
|
| Middle Aged | 10 | 2024 | 25992 | 0.120 |
Why?
|
| Aluminum Silicates | 1 | 2014 | 3 | 0.120 |
Why?
|
| DNA Mismatch Repair | 2 | 2024 | 48 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 101 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 332 | 0.110 |
Why?
|
| Adult | 9 | 2024 | 29010 | 0.110 |
Why?
|
| Diarrhea | 1 | 2014 | 315 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 673 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1660 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2020 | 12123 | 0.090 |
Why?
|
| Young Adult | 4 | 2020 | 8836 | 0.080 |
Why?
|
| Male | 10 | 2024 | 60081 | 0.080 |
Why?
|
| Depsipeptides | 1 | 2008 | 10 | 0.080 |
Why?
|
| Female | 10 | 2024 | 65528 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1213 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 126 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1591 | 0.070 |
Why?
|
| Neoplasms | 1 | 2020 | 2758 | 0.060 |
Why?
|
| Humans | 10 | 2024 | 123072 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1590 | 0.050 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 53 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2016 | 16039 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1008 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2017 | 120 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 299 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 238 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1238 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1473 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 653 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1928 | 0.020 |
Why?
|
| Capecitabine | 1 | 2008 | 16 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 157 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2008 | 63 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2008 | 193 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1682 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1997 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 4513 | 0.010 |
Why?
|